Cerebral and Splanchnic Vein Thrombosis: Advances, Challenges, and Unanswered Questions

JCM, Vol. 9, Pages 743: Cerebral and Splanchnic Vein Thrombosis: Advances, Challenges, and Unanswered Questions:

JCM, Vol. 9, Pages 743: Cerebral and Splanchnic Vein Thrombosis: Advances, Challenges, and Unanswered Questions

Journal of Clinical Medicine doi: 10.3390/jcm9030743

Authors:
Nicoletta Riva
Walter Ageno


Cerebral vein thrombosis (CVT) and splanchnic vein thrombosis (SVT) are two manifestations of venous thromboembolism (VTE) at unusual sites. They have an incidence at least 25–50 times lower than usual site VTE, but represent true clinical challenges. Recent evidence on the epidemiology, risk factors, prognosis, and treatment of CVT and SVT has been published in the last two decades, thus contributing to a better understanding of these diseases. The improvement in imaging techniques and a higher degree of clinical suspicion may have led to the observed increased frequency, whereas a better knowledge of provoking mechanisms could have contributed to reducing the proportion of events classified as unprovoked or idiopathic (13%–21% of CVT, 15%–27% of SVT). Few small randomized clinical trials and a number of observational studies, although hampered by heterogeneous therapeutic approaches, shed light on the safety and effectiveness of anticoagulant therapy in these populations. However, there are still some grey areas that warrant future research. In this narrative review, we discuss recent advances and therapeutic challenges in CVT and SVT.